169 related articles for article (PubMed ID: 37568081)
1. Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality.
Fu DJ; Zhang Q; Shi L; Borentain S; Guo S; Mathews M; Anjo J; Nash AI; O'Hara M; Canuso CM
BMC Psychiatry; 2023 Aug; 23(1):587. PubMed ID: 37568081
[TBL] [Abstract][Full Text] [Related]
2. Treatment response to esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or behavior without evidence of early response: a pooled post hoc analysis of ASPIRE.
Turkoz I; Lopena O; Salvadore G; Sanacora G; Shelton R; Fu DJ
CNS Spectr; 2022 Jul; ():1-7. PubMed ID: 35904046
[TBL] [Abstract][Full Text] [Related]
3. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
Fu DJ; Ionescu DF; Li X; Lane R; Lim P; Sanacora G; Hough D; Manji H; Drevets WC; Canuso CM
J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32412700
[TBL] [Abstract][Full Text] [Related]
4. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
Ionescu DF; Fu DJ; Qiu X; Lane R; Lim P; Kasper S; Hough D; Drevets WC; Manji H; Canuso CM
Int J Neuropsychopharmacol; 2021 Jan; 24(1):22-31. PubMed ID: 32861217
[TBL] [Abstract][Full Text] [Related]
5. Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior.
Canuso CM; Ionescu DF; Li X; Qiu X; Lane R; Turkoz I; Nash AI; Lopena TJ; Fu DJ
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):516-524. PubMed ID: 34412104
[TBL] [Abstract][Full Text] [Related]
6. Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).
Jamieson C; Canuso CM; Ionescu DF; Lane R; Qiu X; Rozjabek H; Molero P; Fu DJ
Qual Life Res; 2023 Nov; 32(11):3053-3061. PubMed ID: 37439961
[TBL] [Abstract][Full Text] [Related]
7. Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray.
Turkoz I; Nelson JC; Wilkinson ST; Borentain S; Macaluso M; Trivedi MH; Williamson D; Sheehan JJ; Salvadore G; Singh J; Daly E
Psychiatry Res; 2023 May; 323():115165. PubMed ID: 37019044
[TBL] [Abstract][Full Text] [Related]
8. Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies.
Turkoz I; Daly E; Singh J; Lin X; Tymofyeyev Y; Williamson D; Salvadore G; Nash AI; Macaluso M; Wilkinson ST; Nelson JC
J Clin Psychiatry; 2021 Jul; 82(4):. PubMed ID: 34288609
[No Abstract] [Full Text] [Related]
9. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire.
Kern Sliwa J; Naranjo RR; Turkoz I; Petrillo MP; Cabrera P; Trivedi M
CNS Spectr; 2024 Jun; 29(3):176-186. PubMed ID: 38557430
[TBL] [Abstract][Full Text] [Related]
10. Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability.
Jha MK; Williamson DJ; Magharehabed G; Turkoz I; Daly EJ; Trivedi MH
J Affect Disord; 2023 Jan; 321():153-160. PubMed ID: 36273682
[TBL] [Abstract][Full Text] [Related]
11. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM
J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274
[TBL] [Abstract][Full Text] [Related]
12. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
13. Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray.
Rozjabek H; Li N; Hartmann H; Fu DJ; Canuso C; Jamieson C
J Patient Rep Outcomes; 2022 Jul; 6(1):74. PubMed ID: 35816217
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of esketamine nasal spray in addition to standard of care in patients with major depressive disorder who have active suicidal ideation with intent: A subgroup analysis of the Asian cohort of ASPIRE I (a randomized, double-blind, placebo-controlled study).
Hong JP; Malek AZA; Li CT; Paik JW; Sulaiman AH; Madriaga G; Zhuo J; Siggins S; Fu DJ; Ju PC
Asia Pac Psychiatry; 2023 Dec; 15(4):e12548. PubMed ID: 37771084
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Canuso CM; Singh JB; Fedgchin M; Alphs L; Lane R; Lim P; Pinter C; Hough D; Sanacora G; Manji H; Drevets WC
Am J Psychiatry; 2018 Jul; 175(7):620-630. PubMed ID: 29656663
[TBL] [Abstract][Full Text] [Related]
16. Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant.
Jamieson C; Popova V; Daly E; Cooper K; Drevets WC; Rozjabek HM; Singh J
Health Qual Life Outcomes; 2023 May; 21(1):40. PubMed ID: 37158911
[TBL] [Abstract][Full Text] [Related]
17. Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial.
Zhou Y; Lan X; Wang C; Zhang F; Liu H; Fu L; Li W; Ye Y; Hu Z; Chao Z; Ning Y
J Am Acad Child Adolesc Psychiatry; 2024 May; 63(5):507-518. PubMed ID: 37414272
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
Castro M; Wilkinson ST; Al Jurdi RK; Petrillo MP; Zaki N; Borentain S; Fu DJ; Turkoz I; Sun L; Brown B; Cabrera P
CNS Drugs; 2023 Aug; 37(8):715-723. PubMed ID: 37558912
[TBL] [Abstract][Full Text] [Related]
19. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX
J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
